Formation and persistence of benzo(a)pyrene metabolite-DNA adducts. by Stowers, S J & Anderson, M W
Environmental Health Perspectives
Vol. 62, pp. 31-39, 1985
Formation and Persistence of
Benzo(a)pyrene Metabolite-DNA Adducts
by S. Jill Stowers* and Marshall W. Anderson*
Benzo(a)pyrene (BP) and other polycyclic aromatic hydrocarbons (PAH) are ubiquitous environmental
pollutants and are suspected to be carcinogenic in man. The in vivo formation of BP metabolite-DNA
adducts has been characterized in a variety of target and nontarget tissues of mice and rabbits. Tissues
included were lung, liver, forestomach, colon, kidney, muscle, and brain. The major adduct identified in
each tissue was the (+)-7,B,8a-dihydroxy-9a,lOa-epoxy-7,8,9,10-tetrahydro-BP (BPDEI)-deoxyguanosine
adduct. A713,8a-dihydroxy-93,1013-epoxy-7,8,9,10-tetrahydro-BP (BPDEII)-deoxyguanosine adduct, a(-)-
BPDEI-deoxyguanosine adduct, and an unidentified adduct were also observed. The adduct levels are
unexpectedly similar in all the tissues examined from the same BP-treated animal. For example, the
BPDEI-DNA adduct levels in muscle and brain ofmice were approximately 50%o ofthose in lung and liver
at each oral BP dose used. We have also examined adduct levels formed in vivo in several cell types of
lungandliver. Macrophages, type IIcells, andClaracellsfrom lungandhepatocytes andnonpparenchymal
cells from liver were isolated from BP-treated rabbits. BPDEI-deoxyguanosine adduct was observed in
each cell type and, moreover, the levels were similar in various cell types. These and previous results
strongly suggest that DNA in many human tissues is continuously damaged from known exposure of
humans to BP and other PAH. Moreover, DNA adducts formed from BP are persistent in lung and brain.
The persistence of adducts in cell types that have slow turnover rates could result in significant accu-
mulation ofadducts from long-term exposure to low levels ofBP. BPDEI-DNA adducts and other bulky
adducts are known to inhibit replication and transcription in in vitro systems. Even if environmental
exposure toPAH is too lowtoinduceneoplasia, theaccumulation ofDNAadductsmayproduceaberrations
in transcripts of genetic information in various cells and lead to other toxic effects. Thus, further eluci-
dation ofthe mechanism by which BP(PAH) metabolites bind to DNA ofspecific cell types and ofthe cell-
selective repairofthe adducts shouldenhance ourunderstanding ofthe potential healthriskfrom exposure
to this class of environmental pollutants.
Introduction
Benzo(a)pyrene (BP) and other polycyclic aromatic
hydrocarbons (PAH) are ubiquitous environmental pol-
lutants produced mainly by industrial and transporta-
tional sources (1,2). Since these compounds are
carcinogenic in laboratory animals and since human ex-
posure to these compounds in food, air and water has
been increasing, these chemicals pose a threat as po-
tential human carcinogens.
Laboratory studies as well as epidemiological studies
support this idea (3-12). PAH induce tumors in various
tissues of animal species, regardless ofroute ofadmin-
istration. One model of BP-induced neoplasia is the in-
tratracheal administration to hamsters of BP adsorbed
to particulate matter such as Fe2O3 (13). This causes
respiratory tract tumors in the hamster and is relevant
to human exposure, since atmosphere BP is also ad-
sorbed to particulates. Epidemiological studies on health
effects of PAH, though difficult to obtain because of
widespreadbutlow orvaried exposure, haveshownthat
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gas production workers and coal tar pitch workers do
have higherincidences oflung cancerin addition to skin
and bladder cancers (14-18). Living in areas with high
pollution increases lungcancer incidence (19-21). Stud-
ies have also shown that cigarette smokingis the major
cause oflung cancer (20,22). All ofthese conditions re-
sult in exposure to PAH as well as other classes of
carcinogens.
Themechanism(s)bywhichBPandotherPAHinduce
neoplasia are quite complicated. In the body, these li-
pophiliccompoundsareoxidativelymetabolizedtoepox-
ides, phenols, etc. (Fig. 1), by the cytochrome P-450-
dependent monooxygenase and epoxide hydrase. These
metabolites are then conjugated to more hydrophillic
metabolites by various conjugating enzyme systems,
presumably for excretion. Most of the metabolites are
excretedbutsometimestheenzymesystemwillconvert
the parent compound to a more reactive form that can
bind extensively and covalently to cellular macromole-
cules (23-26). This covalent binding ofreactive metab-
olites of PAH to DNA appears to be an essential first
step in PAH-induced neoplasia (23-28). Ifthe cell can-
not repair the damaged DNA before synthesis occurs,STOWERS AND ANDERSON
then replication on the damaged template can result in
a mutation.
Considerable work has been done to elucidate the
structure(s) ofthe reactive metabolite(s) ofPAH which
bindto DNAintheintact cell. Many studies haveshown
that certain diol epoxide derivatives ofBP are the pre-
dominant metabolites which bind to DNA in vivo (29-
32). These diol epoxide derivatives of BP are formed
by the sequential enzymatic action of the cytochrome
P-450-dependent monooxygenase system and epoxide
hydrase (Fig. 2) (23). The (+)-7p,8a-dihydroxy-9a,1lOa-
epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene (BPDEI) is
the major enzymatic metabolite of (-)-trans-7,8-diol
(33), although some (-)-7,,8a-dihydroxy-9p,10-epoxy-
7,8,9,10-tetrahydrobenzo(a)pyrene (BPDEII) is also
formed. BPDEI and BPDEII predominantlybindtothe
2-amino group of guanine residues (Fig. 3). These diol
epoxides can also bind to the N-7 of guanine (34), ad-
enine (35-38) and cytidine (38) and to phosphate resi-
dues (39,40). It should be mentioned that other
metabolites ofBP can also bind to DNA, especially un-
der in vitro conditions; however, in target tissues for
BP-induced neoplasia, BPDEIand BPDEII arethepre-
dominantly characterized adducts (41). Studies have also
shown that other PAH, such as 7-methylbenzanthra-
cene (42,43), benzanthracene (44,45), chrysene (46,47),
and 5-methylchrysene (48), dibenzanthracene (49), 3-
methylcholanthrene (3-MC) (50,51), and dimethylben-
zanthracene (DMBA) (51-55) are alsoconverted tovery
reactive diol epoxides like BPDEI and BPDEII that
bind to DNA in vivo. All ofthese diol epoxides have a
similar structure involving an epoxide ring in the bay
region and, therefore, have been termed "bay region
diol-epoxides" by Jerina and Daly (56).
It is known that bay region diol epoxides are muta-
genic (57-64), havetransformingactivityinmammalian
cells (27,61), are carcinogenic in newborn mice (60,65-
67), and are initiators in the cells ofmouse skin (42,58-
60,65-68). Themutagenicityandcarcinogenicity, added
to the fact that these adducts are formed in vivo leads
to the hypothesis that these adducts play a role in the
initiation of PAH-induced cancer. This report will re-
view the in vivo binding and persistence of PAH me-
tabolite-DNA adducts and their relationship to PAH-
induced neoplasia.
In Vivo Formation of PAH
Metabolite-DNA Adducts
Several PAH have been examined fortheirformation
of DNA adducts in vivo. In this section, the in vivo
DNA binding of four PAH: BP, 3-MC, DMBA, and
15,16-dihydro-11-methylcyclopenta[a]phenanthrene-17-
one (11-methyl ketone) will be discussed. BP, the most
extensively studied PAH, will be the topic of most of
this discussion.
BP metabolites are known to bind to DNA in nu-
merous tissues ofdifferent animal species. Stowers and
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FIGURE 1. The major pathways involved in the metabolism of benzo(a)pyrene. Initial oxidations of BP-catalyzed by monooxygenases (MO)
mayresult in 6-OH-BP or epoxide formation. 6-OH-BP is oxidized to form quinones. Epoxides may spontaneously rearrange to form phenols
orform glutathione conjugates, orbe further oxidized by epoxide hydrase (EH) to form dihydrodiols. The dihydrodiols maythenbe activated
to the carcinogenic form, the diol epoxide, by the MO. Many of these metabolites may be enzymatically converted to glucuronide sulfate
or glutathione conjugates as indicated in the figure. Enzyme notation is as follows: MO, monooxygenase; EH, epoxide hydrase; QR, quinone
reductase; U, glucuronyltransferase; GT, glutathione transferase, S, sulfotransferase.
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FIGURE 2. Formation of ultimate carcinogenic form of
benzo(a)pyrene. Shown are the enzymatic steps involved in the
formation of BP-7,8-diol-9,10-oxide. Monooxygenases oxidize BP
toform the epoxide intermediate (not shown) and epoxide hydrase
converts the epoxide to the dihydrodiol. The (-)-BP-7,8-diol form
shownhere isthepredominate stereoisomeric formproducedfrom
this reaction. The second oxidation in the two-step oxidation pro-
cess is also catalyzed by monooxygenases and results in the pro-
duction of (+)-BPDEI, the major metabolite that binds to the
nucleophilic sites on DNA, and (-)-BPDEII, another metabolite
that binds to DNA. Diol epoxides formed from the (+)-BP-7,8-
diol enantiomer are (-)-BPDEI and (+)-BPDEII and are found
to bind to DNA to a lesser extent.
Anderson (30) have shown that BPDEI and BPDEII
bind to lung, liver, colon, kidney, muscle, brain, and
forestomach ofthe A/HeJ mouse and to the lung, liver,
colon, muscle, brain, and blood of the New Zealand
White rabbit (Tables 1 and 2). Eastman et al. (32) ob-
served the formation of BP metabolite-DNA adducts
inlung, liver, and kidney ofmice. Dunn et al. (31) showed
that BP metabolites bind to DNA in liver, stomach,
colon, and intestine of Swiss mice following oral doses
of BP. The adduct levels in liver and intestines were
similar and these levels were 2 to 4 times higher than
those in stomach and colon. Several investigators have
shown that BPmetabolites alsobind to DNA inthe skin
of several mouse strains (29,69-75). In all cases, the
major metabolite is the (+)-BPDEI bound to the N-2
ofguanine residues as shown in Figure 4. As shown in
the chromatogram, other adducts are also consistently
observed invivo: (-)-BPDEI-dGuo, BPDEII-dGuo and
an unidentified peak. BPDEI and BPDEII may also
bind to adenine residues except in smaller amounts. It
is important to note that these adducts are formed in
both tissues susceptible to PAH-induced neoplasia (tar-
get tissues) and tissues resistant to PAH-induced neo-
plasia. Similar adduct patterns are seen in each examined
tissue in mice and rabbits regardless of dose, route of
administration, or time of sacrifice after dosing (30).
In addition to similar adduct patterns in different tis-
sues and species, it is surprising to find that the levels
of the BP metabolite-DNA adducts are similar in tis-
sues of the same BP-treated animal and that this sim-
ilarity in adduct levels is independent of the oral dose
level. As seen in Table 1, Stowers and Anderson (30)
observed similar (+)-BPDEI-dGuo adduct levels in
several tissues ofthe A/HeJ mouse. Atboth dose levels
ofBP, there was no more than a 2-fold difference in the
specific activities of the BPDEI-dGuo adduct in the
seventissuesexamined. Adriaenssensetal. (76)showed
similar results in the lung, liver, and forestomach of
mice over a wider dose range of 2 to 1351 ,umole/kg.
These studies suggest no first pass effect in the liver
for adduct formation after oral administration of BP to
mice.
Similar BP metabolite-DNA adduct levels may also
be seen after IV administration of BP. Table 2 shows
that (+)-BPDEI-dGuo levels in several tissues of the
rabbit after an IV dose of 4 ,mole BP/kg. The liver,
brain, and colon had the same adduct levels while the
adduct levels in the muscle and blood were slightly
higher. The levels of (+)-BPDEI-dGuo adduct in the
lungwere even higher, almost three to fourtimes those
in the other tissues. Eastman et al. (32) saw a similar
pattern of binding levels in the A/J mouse after IV
administration of BP. The levels of (+)-BPDEI-dGuo
in the lung were three to five times those in the liver
orkidney. AnotherstudybyEastman andBresnick(77)
with a different PAH, 3-MC, shows the similar pattern
ofrelative binding ofadducts in various tissues after an
IV dose in several mouse strains. In the four mouse
strains examined, there is a 2- to 4-fold higher amount
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FIGURE 3. Interaction of(+)-BPDEI and deoxyguanosine to form a DNA adduct. (+)-BPDEI spontaneously decomposes to the carbonium
ion triol internediate. The electrophilic intermediate then interacts nonenzymatically with the nucleophilic sites on the DNA. Illustrated
here is (+)-BPDEI binding to the N-2 ofguanosine.
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FIGURE 4. HPLC ofBPmetabolite-deoxyribonucleoside adductsin
New Zealand White rabbit lung IV dose of BP. Rabbits were
sacrificed 24 hr after an oral dose of 3H-BP (4 ,mole/kg). DNA
isolated from these tissues was enzymatically digested and the
deoxyribonucleosides were chromatographed on HPLC (30). WF,
water fraction; GF, gradient fractions. Peaks II, III, and IV have
been identified as (-)-BPDEI-dGuo, (+)-BPDEI-dGuo, and
BPDEII-dGuo adducts, respectively. Peak I is discussed else-
where (30). The specific activities (pmole/mg DNA) ofthe adducts
are given in Table 2. The arrows (l) denote positions of the
internal standards (MB, methyl-p-hydroxybenzoate; PB, propyl-
p-hydroxybenzoate; and 9,10-diol, BP-9,10-diol).
of3-MC metabolites bound to DNA in the lung than in
the liver. These reports indicate that there is a first-
pass effect in the lung for adduct formation after IV
adminstration of BP as well as other PAH causing the
higher relative binding of PAH metabolites to DNA of
the lung.
In contrast to mice and rabbits, no generalization can
be made at present on the binding ofBP metabolites to
DNA of rat tissue. In the study by Boroujerdi et al.
(78), theBPDEI-dGuo adductwasnotthemajoradduct
observed in lung and liver 1 hr after an IV dose ofBP.
Table 1. BPDEI-dGuo adduct levels in various
tissues ofA/HeJ mouse.a
Adduct levelsb
Low dose High dose
Tissue (11.9 ,umole/kg) (1190 ,umole/kg)
Lung 0.028 6.1
Liver 0.019 5.4
Forestomach 0.031 5.5
Brain 0.012 2.9
Kidney 0.014 3.3
Colon 0.013 2.7
Muscle 0.014 3.2
'A/HeJ mice were sacrificed 48 hr after an oral dose of'H-BP. The
mice were divided into two groups of 30 mice: one group received
11.9 ,mole/kg and another group received 1190 ,umole/kg. DNA was
isolated from each pooled tissue (lung, liver, forestomach, brain, co-
lon, kidney, and muscle) and enzymatically digested to deoxyribo-
nucleosides. The deoxyribonucleosides were chromatographed on
HPLC.
bThese numbers represent the specific activity (pmole/mg DNA)
ofthe (+)-BPDEI-dGuo (peak III in the chromatogram in Fig. 2).
The major adduct formed probably results from the in-
teraction of 9-hydroxy-BP-4,5-oxide with DNA. How-
ever, Baer-Dubowska and Alexandrov (79) observed the
same proffle in rat skin as seen in mouse after topical
application of BP. It is also interesting that studies in
cultured rat hepatocytes yield confficting data: Ashurst
and Cohen (80) observed that the BPDEI-dGuo as the
major adduct whereas Jernstrom et al. (81) observed
the samemajoradduct as seenby Boroujerdi et al. (78).
Obviously, more data are needed to resolve these dif-
ferences observed in BP metabolite-DNA adduct pro-
ifies in rat tissue. In any case, as in rabbit and mouse,
adducts were observed in each tissue examined and in
the study by Boroujerdi et al. (78), the adduct binding
levels were similar in lung and liver.
DMBA binding to DNA has been studied in the skin
ofseveral mouse strains (69). In all mouse strains stud-
ied, Sephadex LH20chromatography ofthe DMBAme-
tabolite-deoxyribonucleoside adducts in the skin were
similar, with three peaks being observed (69). The ma-
jor DMBA-DNA adducts appear to arise through the
reaction of the bay region diol epoxide of DMBA with
deoxyguanosine and deoxyadenine residues in DNA.
Abbott and Crew have examined the in vivo binding
of 11-methyl ketone metabolites to DNA in lung, liver
and skin of TO mice (82,83). The major adduct was
formed from the interaction of the anti-3,4-dihydro-
3,4,trans-dihydroxy-1,2-dihydro-1,2-epoxidemetabo-
lite with deoxyguanosine (84). This diol epoxide bound
to deoxyguanosine was observed regardless of tissue
susceptibility to PAH-induced neoplasia or route of
administration (intramuscular, topical, or intraperito-
neal). Similar total carcinogen-DNA binding levels were
also seen in the three tissues after intravenous
adminstration.
There are several possible explanations for the bind-
ing of PAH metabolites to the DNA ofall tissue ofthe
mouse and rabbit that have been studied. It is possible
that oxidative metabolism ofPAH in each tissue is suf-
ficient to account for the observed DNA binding since
monooxygenase activity has been detected in most tis-
sues (85,86). However, with BP, there is obviously no
correlation between the cytochrome P-450-dependent
monooxygenase activity and the DNAbinding. Because
there is a 400-fold difference between mouse brain mi-
crosomes and livermicrosomes in the metabolism ofBP
(87), it is surprising to see only a 2-fold difference in
the BPDEI-dGuo adduct between the two tissues. An-
other incongruity is that the muscle, a tissue that has
nodetectableactivity, stillshowsanappreciableamount
ofbindinginthe mouseandtherabbit. Anotherpossible
cause of similar adduct levels in various tissues could
be compartmentalization of some cytochrome P-450 ac-
tivityinthenucleus; althoughnodatahasbeenobtained
to support this theory.
Other studies suggest that transport via a carrier
protein can be responsible for the presence of BP me-
tabolites in cells unable to metabolize this carcinogen.
Hanson-Painton et al. (88) have shown that cytosolic
proteins that transport BP from microsomes do exist.
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Table 2. BPDEI-dGuo adduct levels in rabbits after IV administration of BP.'
Adduct levels as specific activity, pmole/mg DNA
Tissue 1 2 3 4 5 6 7 Mean + SD
Lung 0.071 0.040 0.054 0.054 0.047 0.062 0.077 0.058 ± 0.013
Liver 0.017 0.018 0.020 0.015 0.017 0.014 0.015 0.017 ± 0.0002
Brain 0.018 0.013 0.015 0.011 0.0098 0.024 0.018 0.016 0.005
Colon 0.026 0.014 0.015 b_- 0.018 0.007
Muscle 0.033 0.012 0.057 - 0.034 ± 0.023
Blood 0.029 0.030 0.038 - 0.032 ± 0.005
aNew Zealand White rabbits were sacrificed 24 hr after an IV dose of3H-BP (4 ,umole/kg). DNA was isolated from each tissue and was
enzymatically digested to the deoxyribonucleosides and chromatographed on HPLC. Shown here are the specific activities (pmole/mg DNA)
ofthe major adduct (+) BPDEI-dGuo.
bSpecific activity of a peak not quantitated unless the counts in the peak were at least 100 dpm above background.
Others have shown a similar cytosolic protein to bind
to and transport 3-MC. These proteins probably bind
and transport BP and other PAH to their site of me-
tabolism in microsomes (89-91). Lo et al. (92) postulate
the presence ofsuch a carrier for BPDEI in human and
mouse cells. Sebti et al. (93) have shown that metabo-
lism of BP in one cell type (activator cell) can result in
the binding ofBPDEI and BPDEII to DNA in another
celltype(targetcell). TheactivatedBPmetabolitesbind
to the carrier molecule, are transported from activator
cells to target cells and bind to the DNA in the target
cells. The transfer ofthese activated metabolites from
one cell to another appears to be very efficient. The
transport of diol epoxide metabolites of PAH may be
important to the formation of DNA adducts in tissues
oflow metabolic capabilities.
Several dose-response studies for PAH metabolite-
DNA adducts have been reported. Phillips et al. (69)
treated C57BL/6J mice topically with DMBA at arange
of0.025 to 1.0 ,umole/mouse. Three DMBA metabolite-
DNA adducts, as determined by Sephadex LH20 chro-
matography, were present at each dose. They found
that the formation of DMBA metabolite-DNA adducts
in mouse skin varied nonlinearly with dose. Pereira et
al. (71) examined the formation ofepidermal BP-DNA
adductsinICR/Hamice aftertopicaldosesrangingfrom
0.01 to 300 mg/mouse. The binding of BP metabolites
to DNA wasessentially linearthroughout the dose range.
Adriaenssens et al. (76) investigated the binding ofBP
metabolites to DNA in lung, liver, and forestomach of
A/HeJ mice after oral doses ranging from 0.048 to 29.7
,umole/mouse. In lung and liver, the dose-response curve
were sigmoidal whereas the forestomach dose-response
curvewasmorelinear. Ineachofthese studiesthedose-
response relationships for PAH metabolite-DNA ad-
ductsapproached linearity atlow dosesand, thus, there
does not appear to be athreshold dose below which the
binding of PAH metabolites to DNA does not occur.
In summary, PAH metabolites have been found to
bind to DNA in vivo in every tissue that has been ex-
amined. This occurs regardless of species, dose, and
route of administration. It is also quite surprising to
find that similar levels ofadducts are formned in vivo in
the various tissues of the same PAH-treated animal
whether the tissue is a target for PAH-induced neopla-
sia or not. Small differences in the relative binding lev-
els are most likely due to route of administration and
probable first-pass effects in particulartissues. The ma-
jor PAH metabolite-DNA adduct observed has been a
bay region diol epoxide metabolite bound to a deoxy-
guanosine residue. Previous studies have shown that
this bay region diol epoxide-deoxyguanosine adduct is
also the major adduct formed in human cell culture in-
cubated with BP. These findings have strong toxicolog-
ical implications because of the low but continuous
exposure of humans to BP and other PAH in the
environment.
Persistence and Repair of Adducts
Several in vivo studies have attempted to determine
if persistence of PAH metabolite-DNA adducts in a
particular tissue is causally related to its susceptibility
to PAH-induced neoplasia. The data of Kulkarni et al.
on persistence of BPDE adducts offer no explanation
for the strain difference in susceptibility to BP-induced
pulmonary adenoma(94). The datasuggestthat adducts
maybemore persistent inlungsoftheresistant C57BL/
6J strain than in the susceptible A/HeJ strain (Fig. 5).
Several other studies are in agreement with this con-
clusion. Phillips et al. (69) showed that there was no
correlation between persistence of DMBA metabolite-
DNAadductsinmouseskinandsusceptibilityofvarious
mice to PAH-induced neoplasia. Similar conclusions were
reachedwith BPand3-MC, althoughadductlevelswere
examined at only two time points (32). Pelkonen et al.
(95) examined the disappearance ofBP metabolite-DNA
adducts in skin and subcutaneous tissues of C3H and
C57BL/6 mice. The rates of disappearance of the ad-
ducts do not differentiate between the C57BL/6 resist-
ance and the C3H susceptibility to BP-initiated
subcutaneous fibrosarcomas. In contrast, Eastman and
Bresnick (77) reported that the persistence of 3-MC
metabolite-DNAadducts inmouselungcorrelatedwith
susceptibility of the various mouse strains to 3-MC-in-
duced pulmonary adenomas (Fig. 5). The reasons for
the discrepancy between the results of Eastman and
Bresnick (77) and the other studies are unclear. In gen-
eral, persistence ofPAHmetabolite-DNAadductsdoes
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FIGURE 5. Disappearance of PAH metabolite-DNA adduct over
time in mouse lung. The nucleoside-bound adduct per milligram
of DNA is shown on the ordinate as a percent of the initial level
of adduct: (LO) Disappearance of 11-methyl ketone metabolite-
DNA adduct in lung of TO mice (83); (0), (A) disappearance of
BP metabolite-DNA adducts in lungs of A/HeJ and C57BL/6J
strains of mice, respectively (94); (AU, , 0, 0) disappearance of
3-MC metabolite-DNA adducts in lungs of A/J, C3H/HeJ, DBA/
2J, and C57BL/6J strains of mice, respectively (77).
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FIGURE 6. Disappearance of PAH metabolite-DNA adduct over
time in mouse liver. The nucleoside-bound adduct per milligram
of DNA is shown on the ordinate as a percent of the initial level
of adduct: (E) disappearance of 11-methyl ketone metabolite-
DNA adducts in livers of TO mice (83); (0, A) disappearance of
BP metabolite-DNA adducts in livers of A/HeJ and C57BL/6J
strains of mice, respectively (94); (U,*, 0, x) disappearance of
3-MC metabolite-DNA adducts in livers ofA/J, C3H/HeJ, DBA/
2J, C57BL/6J strains of mice, respectively (77).
not explain tissue susceptibility to PAH-induced neo-
plasia in various mice strains. However, it should be
emphasized that the specific activities ofthe PAH me-
tabolite-DNA adductsreportedintheabove-mentioned
studies are calculated on the basis ofthe total DNA in
the organ. It is possible that the amounts of adducts
formed aswell astheirrepairratesindifferentcelltypes
ofthetarget organ may varyconsiderably. Examination
of the formation and persistence of PAH metabolite-
DNAadducts inindividual celltypes ofthetargettissue
might allow differentiation of tissues with respect to
susceptibility and resistance to PAH-induced neoplasia.
A summary ofthe in vivo disappearance ofPAH me-
tabolite-DNA adducts in lung and liver ofvarious mice
strainsis illustrated inFigures 5 and 6. Theadductlevel
present in the tissue at a given time point is expressed
as a percent of the initial value measured after admin-
istration of the PAH. The variations in disappearance
rates are much greater in liver than in lung. In fact,
thesimilarityindisappearanceratesinlungis surprising.
Measurements of in vivo disappearance rates may
reflect enzymatic excision repair; however, cell turn-
over can also account for adduct disappearance. In a
recentstudy, KulkarniandAnderson(96) examinedBP-
induced unscheduled DNA synthesis (UDS) in lung and
liver of A/HeJ mice. UDS is a direct measurement of
excisionrepair. BPinduced UDS in liverbut not inlung
at the doses and time points examined. The procedure
was able to detect UDS in lung, since 4NQO-induced
UDS was observed (96). Thus the observed disappear-
ance of BPDE adducts in liver of A/HeJ mice (Fig. 6)
is due, at least in part, to excision repair whereas the
disappearance in lung (Fig. 5) results from cell turnover
(96). Abbott and Crew (83) also showed that normal
DNA turnover rates could account for the disappear-
ance of DNA adducts formed from metabolites of 11-
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methyl ketone in lungs and skin of mice whereas exci-
sion repair was probably involved in removal ofadducts
from liver. Thus, both excision repair and cell turnover
must be considered in assessing the mechanisms of in
vivo removal of carcinogen metabolite-DNA adducts.
The presence of excision repair in the liver and the
low rate of DNA synthesis by this tissue may provide
an explanation for the relative resistance ofthis tissue
to carcinogenesis by BP, since, under altered conditions
of DNA replication following hepatectomy, tumors can
be induced by PAH treatment (12,97,98). In contrast
to the liver, the lack of excision repair in vivo of BP
metabolites and the relatively high rate of DNA turn-
overin lung may be favorable conditions forthe fixation
of promutagenic lesions. The same arguments would
hold for 11-methyl ketone, sincelungand skinaretarget
tissues whereas the liver is resistant to carcinogenesis
by 11-methylketone undernormal conditions. Thus, the
balance between DNA repair and DNA replication is
an important consideration in the study ofmutagenesis
and carcinogenesis.
Insummary, DNAadductsformed fromBPandother
PAH are relatively persistent in tissues such as lung,
skin, and brain. Persistence of PAH metabolite-DNA
adducts in these tissues could be the result ofparticular
cell types lacking excision repair. Ifthese celltypes also
have slow turnover rates, accumulation of significant
levels of PAH metabolite-DNA adducts could occur,
especially if there is continuous long-term exposure of
even low levels of PAH. The result of the persistence
of bulky adducts on the DNA template could be inhi-
bition of replication or transcription (99). Even if en-
vironmental exposure to PAH is too low to be
tumorigenic, the persistence ofDNA adducts may pro-
duce aberrations in transcripts of genetic information
in various organs and lead to other toxic effects.
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